Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
STUDY DESIGN
Structure:
Multicenter, randomized, double-masked, vehicle-controlled, parallel group study.
Duration:
3 months of TID treatment.
Treatment Groups, Dosing, and Treatment Regimen:
Study Treatment: CBT-006 topical ophthalmic solution Control Treatment: CBT-006 vehicle